Uro­Gen steers to­wards its first com­mer­cial drug launch, armed with strong da­ta on lead ther­a­py

Uro­Gen is stay­ing right on track to its first drug launch with­in the first 6 months of 2020. And they are al­ready build­ing up their com­mer­cial wing to make it work.

The New York-based biotech $URGN post­ed up­dat­ed Phase III da­ta on their lead drug, UGN-101, which demon­strat­ed a 59% com­plete re­sponse rate among 71 pa­tients suf­fer­ing from low-grade up­per tract urothe­lial can­cer. At 6 months, dura­bil­i­ty hit 89%; at 12 months it was 84%. Close to half — 34 —  were not el­i­gi­ble for surgery and of those, 20 had achieved a com­plete re­sponse with iden­ti­cal dura­bil­i­ty records.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER